On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help ...

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

BERKELEY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results ...

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold 395,617 shares of CRISPR Therapeutics AG during the third quarter. Its ...

ARK also continued its buying trend in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 39,250 shares valued at $2,142,265. This purchase adds to the fund’s recent accumulation of CRISPR stock over the ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

Investing.com -- Intellia Therapeutics Inc (NASDAQ:NTLA) stock soared 13.8% in premarket trading Monday after the gene editing company presented positive clinical data for its hereditary angioedema ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...